@article {doi:10.1021/acs.jmedchem.3c01151,
	title = {Rearmed Bifunctional Chelating Ligand for 225Ac/155Tb Precision-Guided Theranostic Radiopharmaceuticals-H4noneunpaX},
	journal = {J. Med. Chem.},
	volume = {66},
	number = {19},
	year = {2023},
	note = {PMID: 37738446},
	month = {09/2023},
	pages = {13705-13730.  Invited for Virtual Special Issue {\textquotedblleft}Diagnostic and Therapeutic Radiopharmaceuticals{\textquotedblright}},
	abstract = {<p>{ Superior bifunctional chelating ligands, which can sequester both α-emitting radionuclides (225Ac, 213Bi) and their diagnostic companions (155Tb, 111In), remain a formidable challenge to translating targeted alpha therapy, with complementary diagnostic imaging, to the clinic. H4noneupaX, a chelating ligand with an unusual diametrically opposed arrangement of pendant donor groups, has been developed to this end. H4noneunpaX preferentially complexes Ln3+ and An3+ ions, forming thermodynamically stable (pLa = 17.8</p>},
	doi = {10.1021/acs.jmedchem.3c01151},
	url = {https://doi.org/10.1021/acs.jmedchem.3c01151},
	author = {Wharton, Luke and Yang, Hua and Jaraquemada-Pelaez, Maria de Guadalupe and Merkens, Helen and Engudar, Gokce and Ingham, Aidan and Koniar, Helena and Radchenko, Valery and Kunz, Peter and Schaffer, Paul and B{\'e}nard, Francois and Orvig, Chris}
}
